Synergistic effects of Cortex Mori alkaloids combined with Simvastatin in rats with hyperlipidaemia

doi:10.12092/j.issn.1009-2501.2020.03.006

Abstract

Abstract: AIM: To explore the lipid lowering effect of Cortex Mori alkaloids combined with simvastatin on hyperlipidemia rats. METHODS: Hyperlipidemia model was established by feeding golden hamsters with high-fat diet for 6 weeks, and 40 golden hamsters were randomly divided into normal group, model group, Cortex Mori alkaloids group (CMA, 25 mg·kg-1·d-1),simvastatin group (15 mg·kg-1·d-1) and combination group (Cortex Mori alkaloids, 25 mg·kg-1·d-1, simvastatin 15 mg·kg-1·d-1). 2 weeks after the intragastric administration, cardiac blood sampling was used to determine the blood biochemical indexes such as TG，TC，LDL-C，HDL-C, as well as the levels of ALT，AST，CRP， NO，Lp-PLA2.Liver HE staining was used to observe pathological changes, and liver cell lipid deposition was observed by oil red O staining. RESULTS:Compared with the model group, TC levels in combination group were significantly reduced (P<0.05), LDL-C levels in simvastatin group and the combination group were significantly reduced (P<0.05).The level of NO in the combined group was significantly increased (P<0.05), and the difference was statistically significant compared with that in Cortex Mori alkaloids group and simvastatin group (P<0.05) .The levels of CRP were significantly decreased in Cortex Mori alkaloids group, simvastatin group and the combination group (P<0.05).The level of Lp-PLA2 in combination group was significantly reduced (P<0.05). The results of liver HE staining and oil red O staining showed that both of them could improve the hepatic lesion and lipid deposition after drug treatment, and the improvement of the combination group was better than that of the two groups alone. CONCLUSION: Simvastatin combined with Cortex Mori alkaloids can effectively decrease lipid level and inflammatory level of golden hamstrel with hyperlipidemia.Cortex Mori alkaloids can be used as the auxiliary drug of simvastatin, which is expected to provide a new choice for clinical treatment of hyperlipidemia.

Key words: hyperlipidemia, simvastatin, Cortex Mori alkaloids, inflammation, endothelial dysfunction

CLC Number:

LI Jiadan，LU Chen. Synergistic effects of Cortex Mori alkaloids combined with Simvastatin in rats with hyperlipidaemia[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(3): 278-284.

References

［1］Yan L, Xu MT, Yuan L, et al. Prevalence of dyslipidemia and its control in type 2 diabetes: A multicenter study in endocrinology clinics of China［J］. J Clin Lipidol, 2016, 10(1):150-160.
［2］Xu DH,Wang F,Yan W.Comparison of commonly used statins［J］.Chin J Mod Appl Pharm，2018,35(7):1112-1117.
［3］Al Mamun A, Hashimoto M, Katakura M, et al.Effect of dietary n-3 fatty acids supplementation on fatty acid metabolism in atorvastatin-administered SHR.Cg-Lepr/NDmcr rats, a metabolic syndrome model［J］. Biomed Pharmacother, 2017,85:372-379.
［4］谢珍, 康桦, 何立成,等.深海鱼油对高脂血症模型大鼠血脂的影响及机制探讨［J］.中国临床药理学与治疗学, 2017, 22(8):870-874.
［5］Zheng D, Cai A, Xu R, et al. Effects and potential mechanism of atorvastatin treatment on Lp-PLA2 in rats with dyslipidemia［J］. Arch Med Sci,2018, 14(3):629-634.
［6］张静, 高英, 罗娇艳,等.桑白皮不同部位对实验性高脂糖尿病小鼠的影响［J］.中药新药与临床药理, 2014, 25(2):159-164.
［7］Shafik NM, Baalash A, Ebeid AM.Synergistic cardioprotective effects of combined chromium picolinate and atorvastatin treatment in triton X-100-induced hyperlipidemia in rats: impact on some biochemical markers［J］. Biol Trace Elem Res,2017, 180(2):255-264.
［8］Owens AP, Byrnes JR, Mackman N.Hyperlipidemia, tissue factor, coagulation, and simvastatin. Trends in cardiovascular medicine［J］. Trends Cardiovasc Med,2014, 24(3):95-98.
［9］Ahmed M, El Bakly WM, Zaki AM, et al. Bupropion effects on high-fat diet-induced steatohepatitis and endothelial dysfunction in rats: role of tumour necrosis factor-alpha LID［J］. J Pharm Pharmacol,2014, 66(6) :793-801.
［10］Maqbool M, Cooper ME，Kam JD. Cardiovascular disease and diabetic kidney disease［J］. Saudi J Biol Sci, 2018, 38(3):217-232.
［11］姜海, 姜国志, 陈钟,等. 姜黄提取物联合阿托伐他汀钙对高脂血症小鼠降血脂作用的研究［J］.中国临床药理学与治疗学, 2017, 22(1):48-51.
［12］Sever PS, Poulter NR, Chang CL, et al. Evaluation of C-Reactive Protein before and bn-treatment as a predictorof benefit of atorvastatin［J］. J Am Coll Cardiol,2013, 62(8):717-729.
［13］Tellis CC, Tselepis AD. Pathophysiological role and clinical significance of lipoprotein-associated phospholipase A (Lp-PLA) bound to LDL and HDL［J］. Curr Pharm Des,2014, 20(40):6256-6269.
［14］Guo R, Nair S, Zhang Y, et al. Adiponectin deficiency rescues high-fat diet-induced hepatic injury, apoptosis and autophagy loss despite persistent steatosis［J］.Int J Obes, 2017, 41 (9) :1403-1412.
［15］解冰川, 李艳敏, 王彦永,等. MMP-9及hs-CRP与动脉粥样硬化、脑卒中关系的研究进展［J］. 临床误诊误治, 2013, 26(5):97-100.
［16］Younus A, Humayun C, Ahmad R, et al. Lipoprotein-associated phospholipase A2 and its relationship with markers of subclinical cardiovascular disease: A systematic review［J］. J Clin Lipidol,2017,11(2):328-337.
［17］Ikonomidis I, Kadoglou NNP, Tritakis V, et al. Association of Lp-PLA2 with digital reactive hyperemia, coronary flow reserve, carotid atherosclerosis and arterial stiffness in coronary artery disease［J］. Atherosclerosis, 2014, 23 (1):34-41.
［18］Chae JS, Kwak JH, Kim M, et al. Effects of A379V variant of the Lp-PLA2 gene on Lp-PLA2 activity and markers of oxidative stress and endothelial function in Koreans［J］. J Thromb，Thrombolysis, 2014, 38(4):477-484.

[1]	LIAO Mengling, WANG Yan, LUO Jing, WANG Nuoyan, HUA Ling, ZHANG Yu, DENG Fei, YUAN Yue, ZHOU Jun, ZHOU Hong. Molecular mechanism of artesunate attenuates the release of proinflammatory cytokines from macrophages [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 969-978.
[2]	ZHAO Lingzhi, HE Yanjun, XIE Jianqin, YOU Chongge. Research progress on therapeutic role of recombinant human soluble thrombomodulin in atherosclerosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 832-840.
[3]	ZHAO Lu, LI Fuyong, WEN Binhong, LI Daowei. Effects of stains on hyperlipidemia and pain relieve of patients with chronic migraine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 671-675.
[4]	LIANG Hongyu, ZHANG Hailin, YIN Huanxin, CHEN Fan, LU Junlin, ZHU Caihong, HU Wei, ZHOU Renpeng. Effects of 2-APB in skin wound healing in mice through down-regulation of TRPM7 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 747-753.
[5]	MAO Shuying, JIN Wei, FU Sisi, LIU Keanqi, ZHOU Zhihao, WANG Guangji, LIANG Yan. Oral lienal peptides improve ammonia-induced coughing and inflammation in mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 601-607.
[6]	JIN Yiyi, ZHOU Keting, YANG Chengcheng, XU Ping, ZHU Suyan. Osthole attenuates diabetes-induced renal injury by regulating NF-κB and p38/MAPK pathway mediated inflammatory responses [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 622-631.
[7]	CHANG Shufu . Progress of medical treatment of coronary heart disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 405-408.
[8]	WEI Jifang, YUE Hongmei, LIU Nanyu, SONG Peipei, XIE Yingying, WANG Jiaqi, WEI Yaqian. Research progress on the relationship between thyroid hormone and idiopathic pulmonary fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 307-313.
[9]	CHEN Yu, GU Bing, LI Huanan. Modulating gut miocrobiota: a new strategy in the treatment of gout [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1307-1314.
[10]	CHEN Yugang, TU Yanqiong, WANG Congqing, CHEN Juan, ZHANG Bohong. Network pharmacology and molecular docking to discuss the mechanism of Jinhutongdan prescription in the treatment of cholelithiasis and experimental verification [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1090-1098.
[11]	LI Ying, YAO Wei, WANG Meng, YU Zhihong, GONG Yuanqi, LAN Haibing, QI Xiefei. Experimental study of irisin alleviates house dust mite-induced airway epithelial cells inflammation and apoptosis via the NF-κB and JNK signaling pathways [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1106-1112.
[12]	WU Lin, HAO Yingxiang, ZHANG Lei, ZHANG Tianxue, GAO Mingjing, LENG Yufang. Paricalcitol attenuates intestinal ischemia-reperfusion injury in mice through HMGB1/TLR4/NF-κB signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 1-7.
[13]	XU Ke, GAO Junwei, LIU Peng, SHEN Zhengri, JIA Hui, WU Chenguang, TIAN Feng, WANG Lifan, LI Ping. Tangshen formula improves cholesterol uptake and efflux of macrophages induced by high lipid via activating PGC-1α/LXR/ABCA1 pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 978-985.
[14]	WANG Rui, PAN Jinjin, LI Hua, YUAN Yuhui. Research progress of melatonin on pulmonary hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 444-448.
[15]	ZHANG Na, TANG Futian. Protective effect and mechanism of lycium barbarum polysaccharides on diabetic renal injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(11): 1237-1243.